Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia

Blood

Volumn 110, Issue 7, 2007, Pages 2757-2760

  Lilleri, Daniele ^a   Gerna, Giuseppe ^a,b   Furione, Milena ^a   Bernardo, Maria Ester ^a   Giorgiani, Giovanna ^a   Telli, Stefania ^a   Baldanti, Fausto ^a   Locatelli, Franco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; PHOSPHOPROTEIN 65 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INTERMETHOD COMPARISON; LEUKOCYTE; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEWBORN; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE;

EID: 34948871563     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-080820     Document Type: Article

References (17)

1. Boeckh M, Ljungman P. Cytomegalovirus infection after bone marrow transplantation. In: Paya C, ed. Transplant infections. Philadelphia, PA: Lippincott-Raven; 1998;215-227.
2. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-4071.
3. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
4. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 1998;66:1330-1334.
5. Van der Bij W, Schirm J, Torensma R, Van Son WJ, Tegzess AM, The TH. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol. 1988;26:2531-2535.
6. Revello MG, Zavattoni M, Percivalle E, Grossi P, Gerna G. Correlation between immunofluorescent detection of human cytomegalovirus immediate early antigens in polymorphonuclear leukocytes and viremia. J Infect Dis. 1989;160:159-160.
7. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80:1358-1364.
8. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Hematol. 1994;88:64-71.
9. Gerna G, Lilleri D, Baldanti F, et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood. 2003;101:5053-5060.
10. Lilleri D, Baldanti F, Gatti M, et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol. 2004;73:412-418.
11. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes. 2006;13:4-11.
12. Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol. 2006;78:408-416.
13. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol. 1992;30:1232-1237.
14. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol. 1998;36:3585-3589.
15. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood. 2006;108:1406-1412.
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
17. Klein JP, Rizzo JD, Zhang M-J, Keiding N. Statistical methods for analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28:909-915.